puxitatug samrotecan (AZD8205) - AstraZeneca
Puxitatug samrotecan: Data from P1/2 trial (NCT05123482) for solid tumors in 2026 (AstraZeneca) - Mar 17, 2025 - Q4 2024 Results 
P1/2 data • Oncology • Solid Tumor
https://www.astrazeneca.com/content/dam/az/PDF/2024/fy/Full-year-and-Q4-2024-results-clinical-trials-appendix.pdf
 
Mar 17, 2025
 
 
b7d14ed9-48de-492c-adb1-24902aa5807f.png